MedTech News
Surprising finding could pave way for universal cancer vaccine
An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to “wake up” the immune system against cancer.
Scientists develop new tool to identify NF1 cognitive signs earlier
Neurofibromatosis type 1 (NF1) is a rare genetic condition that affects approximately 100,000 Americans. Children diagnosed with the disorder often have motor delays and learning disabilities. Many are also diagnosed with autism or brain tumors.
New advanced imaging technology enables detailed disease mapping in tissue samples
Researchers from Aarhus University—in a major international collaboration—have developed a groundbreaking method that can provide more information from the tissue samples doctors take from patients every day.
Digostics Launches University Trial for At-home Type 1 Diabetes Test
Pioneering Study Aims to Validate Convenient, Early Detection Method for Type 1 Diabetes Outside Clinical Settings
Globus Medical Launches DuraPro™ with Navigation
Next-Generation Oscillating System Enhances Precision and Protects Delicate Tissue in Spine and Cranial Procedures
Fulgent Genetics Secures EU CE Mark for FulgentExome and FulgentPLM
Certification Advances Global Access to Comprehensive Genetic Testing and Precision Medicine Solutions in Europe
FDA says UroMems can conduct study of smart implant for male stress urinary incontinence
UroMems announced that it received FDA investigational device exemption (IDE) approval to begin a first-of-its-kind trial for its smart implant.
Saluda Medical Announces Full U.S. Launch of EVA™ Sensing Technology for Use with the Evoke® SmartLoop™ System
MINNEAPOLIS, July 17, 2025 /PRNewswire/ — Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the full commercial launch of EVA, its next-generation sensing technology, in the United States (U.S.). EVA received U.S. Food & Drug Administration (FDA) approval in December 2024 and is compatible with all commercially implanted Evoke® SmartLoop™ System patients.